Shares of Incyte Corp. (INCY) are falling over 9 percent during Monday's trading despite the announcement of positive data from Phase 3 STOP-HS clinical trial program, evaluating povorcitinib in adults with hidradenitis suppurativa.
Currently, Incyte's stock is moving down 9.30 percent, to $61.55 over the previous close of $67.86 on the Nasdaq. The stock has traded between $50.35 and $83.95 in the past one year.
The studies met their primary goals. Moreover, the company noted that these positive data support the planned regulatory submission of povorcitinib for the treatment of HS worldwide.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.